Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
(1995 - 1996)
2024
2024
Clinical stage biotech company focused on renal disease
2024
2024
Co-head of JP Morgan’s new growth investing effort in healthcare.
2021
Led $50 million growth equity investment into a founder-controlled neurovascular medical device company. Worked with founder to purchase a new 85,000 square foot manufacturing facility and negotiated a sale-leaseback transaction to generate a significant gain on the sale, sourced a first time credit facility and helped with the recruitment of the commercial team. Revenue grew 10x in 1st three years post investment. Employees grew from less than 100 to over 250.
2021
2021
Led minority equity investment in founder controlled business focused on infection prevention and staff safety
2023 - 2024
Recapitalized existing portfolio company focused on infection prevention and surgical staff safety solutions. Restructured the company, turned the company profitable for the first time and created and implemented a new strategic plan focused on profitable growth.
1988
1988
150+ acres of organic vineyards producing unique varietals
2017 - 2024
2017 - 2024
Leading healthcare-focused private capital firm with headquarters in Palo Alto, CA and offices in Shanghai and Beijing, China. Founded in 1996 with over US$6.5 Billion in assets under management. The firm invests across a wide range of sub segments of healthcare including but not limited to specialty pharmaceuticals, biotech, medical devices and services. Focus on commercial stage growth equity and controlling stake private equity investments. Source deals, negotiate and structure transactions and take active board roles on behalf of the firm.
2021 - 2024
2021 - 2024
2022 - 2022
Moved from board of directors to interim CEO role to oversee the transition from a founder run business in the tech-enabled digital pathology lab space. Managed the company, hired a recruiter and brought on an outside CEO and transitioned back to a board position.
2021 - 2024
2021 - 2024
Medical device manufacturer with an innovative robotic solution for dental implant procedures.
2021 - 2024
2021 - 2024
Highly profitable pharma services company with a specialization in solving solubility issues for pharma and biotech customers.
2015 - 2024
2015 - 2024
Revenue stage, FDA-approved gynecology-focused medical device for minimally invasive removal of uterine polyps. Designed for both office-based and OR-based surgery with no capital equipment investment needed.